Nurix Therapeutics (NRIX) Accounts Payables: 2019-2025
Historic Accounts Payables for Nurix Therapeutics (NRIX) over the last 5 years, with Aug 2025 value amounting to $8.6 million.
- Nurix Therapeutics' Accounts Payables rose 119.73% to $8.6 million in Q3 2025 from the same period last year, while for Aug 2025 it was $8.6 million, marking a year-over-year increase of 119.73%. This contributed to the annual value of $11.5 million for FY2024, which is 79.38% up from last year.
- According to the latest figures from Q3 2025, Nurix Therapeutics' Accounts Payables is $8.6 million, which was up 44.59% from $6.0 million recorded in Q2 2025.
- In the past 5 years, Nurix Therapeutics' Accounts Payables registered a high of $11.5 million during Q4 2024, and its lowest value of $2.2 million during Q3 2023.
- Moreover, its 3-year median value for Accounts Payables was $5.9 million (2024), whereas its average is $6.0 million.
- Per our database at Business Quant, Nurix Therapeutics' Accounts Payables tumbled by 63.87% in 2023 and then surged by 119.73% in 2025.
- Over the past 5 years, Nurix Therapeutics' Accounts Payables (Quarterly) stood at $6.7 million in 2021, then fell by 23.85% to $5.1 million in 2022, then increased by 26.40% to $6.4 million in 2023, then surged by 79.38% to $11.5 million in 2024, then skyrocketed by 119.73% to $8.6 million in 2025.
- Its Accounts Payables was $8.6 million in Q3 2025, compared to $6.0 million in Q2 2025 and $8.4 million in Q1 2025.